- AustraliaNorth AmericaWorld
Investing News NetworkYour trusted source for investing success
- Lithium Outlook
- Oil and Gas Outlook
- Gold Outlook Report
- Uranium Outlook
- Rare Earths Outlook
- All Outlook Reports
- Top Generative AI Stocks
- Top EV Stocks
- Biggest AI Companies
- Biggest Blockchain Stocks
- Biggest Cryptocurrency-mining Stocks
- Biggest Cybersecurity Companies
- Biggest Robotics Companies
- Biggest Social Media Companies
- Biggest Technology ETFs
- Artificial Intellgience ETFs
- Robotics ETFs
- Canadian Cryptocurrency ETFs
- Artificial Intelligence Outlook
- EV Outlook
- Cleantech Outlook
- Crypto Outlook
- Tech Outlook
- All Market Outlook Reports
- Cannabis Weekly Round-Up
- Top Alzheimer's Treatment Stocks
- Top Biotech Stocks
- Top Plant-based Food Stocks
- Biggest Cannabis Stocks
- Biggest Pharma Stocks
- Longevity Stocks to Watch
- Psychedelics Stocks to Watch
- Top Cobalt Stocks
- Small Biotech ETFs to Watch
- Top Life Science ETFs
- Biggest Pharmaceutical ETFs
- Life Science Outlook
- Biotech Outlook
- Cannabis Outlook
- Pharma Outlook
- Psychedelics Outlook
- All Market Outlook Reports
ICC Labs issued its interim financial results for its second quarter of 2018.
ICC Labs (TSXV:ICC) issued its interim financial results for its second quarter of 2018.
As quoted in the press release:
ICC Labs is also pleased to announce that has completed the construction of its 124,000 [square feet] greenhouse in Tabio, which is strategically located just north of Bogotá, where the Company intends to produce psychoactive cannabis with up to 20 [percent] of tetrahydrocannabinol (THC) for medicinal purposes, subject to approval of the TSX Venture Exchange.
“We are very enthusiastic about the development of our operations in Uruguay and Colombia. ICC Labs has been able to integrate its production of cannabidiol (CBD) oils in Uruguay using our proprietary CO2 extraction laboratory, which is located in Uruguay’s Free Trade Zone ‘Science Park’ and designed in compliance with the Good Manufacturing Practices (GMP) with the potential production capacity of THC derivatives in Colombia, which currently has the highest percentage (44 [percent]) of the global quota for cannabis assigned by the International Narcotics Control Board. ICC Labs has strengthened its position as one of the largest medicinal cannabis suppliers for the South America market,” commented Alejandro Antalich, CEO of ICC Labs.
During the second quarter of 2018, the Company focused its efforts on completing the construction of the new facilities in Uruguay and Colombia to take steps to expand both business segments.
Click here to read the full press release.
Source: globenewswire.com
Latest News
Investing News Network websites or approved third-party tools use cookies. Please refer to the cookie policy for collected data, privacy and GDPR compliance. By continuing to browse the site, you agree to our use of cookies.